ReviewDiscover oncology2025
The clinical significance of circulating microRNAs as biomarkers in lung cancer diagnosis and prognosis.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer continues to be a major cause of deaths associated with cancer, with a considerable number of patients being diagnosed at more advanced stages of the disease. Circulating microRNAs (miRNAs), which are stable in body fluids, offer promising avenues for non-invasive biomarker identification. Recent advancements have highlighted the utility of specific miRNA signatures in treatment decisions and prognostic evaluations. This review has explored the significant function of circulating miRNAs as promising diagnostic and prognostic biomarkers for lung cancer. Integration of miRNA profiles with clinical parameters has shown potential in predicting treatment responses and patient outcomes. Nevertheless, obstacles persist in standardizing the protocols for isolating and quantifying miRNAs, along with the variability of miRNA expression across various cancer types and stages. Future research focusing on larger, multi-center studies is essential to validate the diagnostic and prognostic capacities of circulating miRNAs and enhance their applicability in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.